[Experimental study on treatment of minimal change nephropathy with Lespedeza michx].
OBJECTIVE
To study the therapeutic effect of Lespedeza Michx in experimental rat model of minimal change nephropathy (MCN).


METHODS
The rat MCN model was reproduced by tail-intravenous injection of Adriamycin. The treatment effect of Lespedeza Michx was determined by the detection of urine protein collection for 24 hours, malondialdehyde (MDA), superoxide dismutase (SOD), ATCO, IL-8, TNF-alpha in serum, and renal histopathological changes were observed by microscope.


RESULTS
Lespedeza Michx could decrease the contents of urine proteinuria, MDA, IL-8, and TNF-alpha in serum, increase SOD level and improved the pathological change of glomeruli.


CONCLUSIONS
Lespedeza Michx was effective on MCN.
Wang
Cai-Yun
CY
Traditional Chinese Medicine Department, First Military Medical University, Guangzhou 510515, China.
Deng
Hong-Zhu
HZ
Li
Hui
H
D000818:Animals; D004317:Doxorubicin; D005419:Flavonoids / Q000302:isolation & purification / Q000494:pharmacology*; D016209:Interleukin-8 / Q000097:blood; D007678:Kidney Glomerulus / Q000473:pathology*; D029884:Lespedeza / Q000737:chemistry; D008297:Male; D008315:Malondialdehyde / Q000097:blood; D009402:Nephrosis, Lipoid / Q000097:blood / Q000139:chemically induced / Q000473:pathology; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D013482:Superoxide Dismutase / Q000097:blood; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D005419:Flavonoids; D016209:Interleukin-8; D014409:Tumor Necrosis Factor-alpha; D008315:Malondialdehyde; D004317:Doxorubicin; D013482:Superoxide Dismutase